Absence of CXCR4 C-Terminal Polymorphisms in HIV-1-Infected and Uninfected Spaniards
Joaquim Peraire(Instituto de Salud Carlos III), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Montserrat Broch(Hospital Universitari Joan XXIII de Tarragona), Cristóbal Richart(Universitat Rovira i Virgili), Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), David Dalmau(University Hospital Mútua de Terrassa), Enric Pedrol(Hospital General de Granollers), M. A. Sambeat, Hernando Knobel(Hospital General de Granollers)
Cited by 2
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143